Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $24,800.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00. Following the transaction, the president now owns 2,920,467 shares of the company’s stock, valued at approximately $36,213,790.80. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Songjiang Ma also recently made the following trade(s):

• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total value of $9,560.56.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Price Performance

Shares of NASDAQ GYRE opened at $9.62 on Thursday. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $27.10. The business’s 50 day moving average price is $12.20 and its two-hundred day moving average price is $12.65.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC grew its stake in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the last quarter. Geode Capital Management LLC lifted its position in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after acquiring an additional 43,840 shares during the last quarter. State Street Corp boosted its holdings in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares during the period. FMR LLC acquired a new position in shares of Gyre Therapeutics in the third quarter valued at approximately $47,000. Finally, Advantage Alpha Capital Partners LP bought a new position in shares of Gyre Therapeutics during the third quarter worth approximately $334,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.